A recent study conducted in the United States has raised concerns about the effectiveness of two widely used injectable medications, semaglutide and tirzepatide, in real-world settings. These medications, which belong to a class of drugs known as GLP-1 receptor agonists, are commonly prescribed for obesity treatment.
However, the study found that patients experienced significantly lower weight loss in everyday use than what was observed in clinical trials. This discrepancy is attributed to two main factors: patients discontinuing the medication earlier than expected and using lower maintenance dosages than those typically prescribed in clinical settings.
The study, which was published on June 10 in the peer-reviewed journal *Obesity*, was conducted by a team of researchers from the Cleveland Clinic in Ohio. Both semaglutide and tirzepatide have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes and chronic weight management.
They have gained popularity due to their effectiveness in helping people lose weight, but the new findings suggest that their real-world performance may not always live up to the results seen in controlled clinical trials.
Additionally, the study highlights the growing availability of these medications outside the U.S. — including in countries like India, where they are now also being prescribed for weight management and diabetes treatment. The findings could influence the way healthcare providers approach the use of these medications in broader populations, particularly as the demand for obesity treatments continues to rise.
Related Topics:
Saqib Saleem Shows Off Muscular Look After Cutting Carbs
6 Low-Calorie Wendy’s Orders for Weight Loss from Fitness Coach
